Osteopore (ASX:OSX) subsidiary Osteopore International partnered with Nasdaq-listed CytoMed Therapeutics to develop scaffold-based cellular products for tissue regeneration, according to a Thursday filing with the Australian Securities Exchange.
Under the 18-month deal, CytoMed's mesenchymal stem cells will be combined with Osteopore's bioresorbable scaffolds, with the two companies establishing an advisory committee to assess co-development and resource utilization opportunities, the filing said.
Osteopore shares rose 3% in afternoon trade.
Price (AUD): $0.04, Change: $+0.0010, Percent Change: +2.63%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。